<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000763</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 215</org_study_id>
    <secondary_id>11192</secondary_id>
    <nct_id>NCT00000763</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma</brief_title>
  <official_title>A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in&#xD;
      patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of&#xD;
      the drug.&#xD;
&#xD;
      Since evidence shows that neovascularization is important in the development of Kaposi's&#xD;
      sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with&#xD;
      the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since evidence shows that neovascularization is important in the development of Kaposi's&#xD;
      sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with&#xD;
      the disease.&#xD;
&#xD;
      Patients are entered at 7 escalating dose levels of TNP-470. (PER AMENDMENT 9/3/96: dose&#xD;
      maximum level changed.) Four patients treated at a given dose level must receive at least 4&#xD;
      weeks of therapy before escalation in subsequent cohorts proceeds. If 50 percent of patients&#xD;
      at a given dose level experience dose-limiting toxicity, the previous dose is defined as the&#xD;
      MTD and an additional two patients are treated at the MTD. Patients receive treatment for 12&#xD;
      weeks, followed by 2 weeks of rest, followed by an additional 12 weeks of treatment. Patients&#xD;
      are followed for 12 weeks post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1997</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>42</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNP-470</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  AZT, ddI, ddC, or d4T provided patients have received at least 2 weeks of this therapy&#xD;
             prior to study entry. (Combination ddI/ddC is not permitted.)&#xD;
&#xD;
          -  MAI prophylaxis.&#xD;
&#xD;
        Required in patients with CD4 count &lt; 200 cells/mm3:&#xD;
&#xD;
        Aerosolized pentamidine, trimethoprim/sulfamethoxazole, or dapsone as PCP prophylaxis.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Cutaneous Kaposi's sarcoma.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Consent of parent or guardian if under 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  This protocol is considered suitable for prison populations.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Peripheral neuropathy (grade 2 or worse).&#xD;
&#xD;
          -  Underlying severe or life-threatening infection with bacterial, viral, fungal, or&#xD;
             protozoal pathogens.&#xD;
&#xD;
          -  Known hypersensitivity to TNP-470, fumagillin, or known related compounds.&#xD;
&#xD;
        PER AMENDMENT 9/3/96:&#xD;
&#xD;
          -  Cataracts.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Combination therapy with ddI/ddC (although these drugs may be administered alone or in&#xD;
             combination with AZT).&#xD;
&#xD;
          -  Anticonvulsive medication.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Antineoplastic drugs.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Systemic or topical anti-Kaposi's sarcoma agents or regimens.&#xD;
&#xD;
          -  Suramin.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Warfarin.&#xD;
&#xD;
          -  Heparin (including heparin flushes).&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Investigational status drugs.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of substantial non-iatrogenic bleeding disorders.&#xD;
&#xD;
          -  History of tumor or malignancies other than Kaposi's sarcoma, with the exception of&#xD;
             completely resected basal cell skin carcinoma or in situ cervical carcinoma.&#xD;
&#xD;
          -  History of seizures within the past 10 years.&#xD;
&#xD;
        PER AMENDMENT 9/3/96:&#xD;
&#xD;
          -  History of cataracts.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Antineoplastic drugs.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Systemic or topical anti-Kaposi's sarcoma agents or regimens.&#xD;
&#xD;
        Excluded within 6 months prior to study entry:&#xD;
&#xD;
          -  Suramin.&#xD;
&#xD;
        Unwilling to refrain from unprotected sexual contact or other activities that may result in&#xD;
        HIV re-infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gill PS</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Dezube B</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - East Campus A0102 CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol. 1998 Apr;16(4):1444-9. doi: 10.1200/JCO.1998.16.4.1444.</citation>
    <PMID>9552050</PMID>
  </reference>
  <reference>
    <citation>Frenkel LM, Wagner LE 2nd, Atwood SM, Cummins TJ, Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol. 1995 Feb;33(2):342-7. doi: 10.1128/jcm.33.2.342-347.1995.</citation>
    <PMID>7714190</PMID>
  </reference>
  <reference>
    <citation>Pluda JM, Wyvill K, Lietzau J, Figg D, Saville MW, Nguyen BY, Foli A, Bailey J, Cooper M. A phase I trial of TNP-470 (AGM-1470) administered to patients with HIV-associated kaposi's sarcoma (KS). Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16:61</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>O-(Chloroacetylcarbamoyl)fumagillol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

